Cover Image
市場調查報告書 - 200950

生殖器濕疣(尖頭濕疣)開發中產品分析

Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2014

出版商 Global Markets Direct
出版日期 內容資訊 英文 47 Pages
價格
生殖器濕疣(尖頭濕疣)開發中產品分析 Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2014
出版日期: 2014年12月15日 內容資訊: 英文 47 Pages
簡介

生殖器濕疣(尖頭濕疣)是一般最常見的性行為感染疾病之一。積極從事性活動的人半數以上在一生的某個時刻,會感染到引起生殖器濕疣的病毒。如名字所示,生殖器濕疣對性器官潮濕的組織起作用。生殖器濕疣的外表,為小型肉色疙瘩的形式(或菜花狀外形)。大多數場合,疙瘩非常小,肉眼無法辨識。

本報告提供全球各國的生殖器濕疣 (尖頭濕疣)治療用開發中產品的開發情形相關分析、開發中產品的最新趨勢,及臨床實驗各階段產品的一覽,再加上主要企業簡介、主要藥物概要(產品概要、功能機制、研究開發(R&D)的發展情形)、最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

生殖器濕疣概要

治療藥的開發

  • 生殖器濕疣的開發中產品:概要
  • 生殖器濕疣的開發中產品:比較分析

各企業開發中的生殖器濕疣治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

生殖器濕疣治療藥:開發中產品一覽(各企業)

生殖器濕疣治療藥的開發企業

  • Helix BioPharma Corp.
  • Inovio Pharmaceuticals, Inc
  • NanoViricides, Inc
  • G&E Herbal Biotechnology Co., Ltd.
  • Anaconda Pharma
  • Foamix Ltd
  • Telormedix SA
  • Genetic Immunity, Inc
  • Xiamen Amoytop Biotech Co., Ltd

生殖器濕疣:治療藥的評估

  • 單劑治療藥的情況
  • 各標的
  • 各行動機制
  • 各投藥法
  • 分子的各類型
  • 各治療分類

藥物簡介

  • 干擾素α-2b
  • SRT-100
  • AP-611074
  • TMX-202
  • INO-3112
  • HerpeCide-I
  • 干擾素α-2b
  • imiquimod
  • HupaDerm疫苗

生殖器濕疣治療藥:最新的藥物簡介

生殖器濕疣治療藥:暫停開發的產品

生殖器濕疣治療藥:停止開發的產品

生殖器濕疣相關產品開發的里程碑

  • 值得注意的最新趨勢、新聞稿(共10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Summary

Global Markets Direct's, 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2014', provides an overview of the Genital Warts (Condylomata Acuminata)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Genital Warts (Condylomata Acuminata)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Genital Warts (Condylomata Acuminata) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Genital Warts (Condylomata Acuminata) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Genital Warts (Condylomata Acuminata) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Genital Warts (Condylomata Acuminata)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Genital Warts (Condylomata Acuminata) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Genital Warts (Condylomata Acuminata) Overview 6
  • Therapeutics Development 7
  • Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview 7
  • Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis 8
  • Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies 9
  • Genital Warts (Condylomata Acuminata) - Pipeline Products Glance 10
  • Clinical Stage Products 10
  • Early Stage Products 11
  • Genital Warts (Condylomata Acuminata) - Products under Development by Companies 12
  • Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development 13
  • Agilvax, Inc. 13
  • Anaconda Pharma 14
  • BioMAS Ltd. 15
  • Foamix Pharmaceuticals Ltd. 16
  • G&E Herbal Biotechnology Co., Ltd. 17
  • Helix BioPharma Corp. 18
  • NanoViricides, Inc. 19
  • Genital Warts (Condylomata Acuminata) - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Target 21
  • Assessment by Mechanism of Action 23
  • Assessment by Route of Administration 25
  • Assessment by Molecule Type 27
  • Drug Profiles 29
  • AP-611074 - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • AS-101 - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • AX-03 - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • HerpeCide-I - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • imiquimod - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • interferon alpha-2b (recombinant) - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • PP-210 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • SRT-100 - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • Genital Warts (Condylomata Acuminata) - Recent Pipeline Updates 39
  • Genital Warts (Condylomata Acuminata) - Dormant Projects 41
  • Genital Warts (Condylomata Acuminata) - Discontinued Products 42
  • Genital Warts (Condylomata Acuminata) - Product Development Milestones 43
  • Featured News & Press Releases 43
  • Dec 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions 43
  • Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 44
  • Mar 22, 2010: Helix BioPharma Corp Achieves Last-Patient-Out In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts 44
  • Sep 22, 2008: Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 45
  • Appendix 46
  • Methodology 46
  • Coverage 46
  • Secondary Research 46
  • Primary Research 46
  • Expert Panel Validation 46
  • Contact Us 47
  • Disclaimer 47

List of Tables

  • Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2014 7
  • Number of Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H2 2014 8
  • Number of Products under Development by Companies, H2 2014 9
  • Comparative Analysis by Clinical Stage Development, H2 2014 10
  • Comparative Analysis by Early Stage Development, H2 2014 11
  • Products under Development by Companies, H2 2014 12
  • Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H2 2014 13
  • Genital Warts (Condylomata Acuminata) - Pipeline by Anaconda Pharma, H2 2014 14
  • Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H2 2014 15
  • Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2014 16
  • Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2014 17
  • Genital Warts (Condylomata Acuminata) - Pipeline by Helix BioPharma Corp., H2 2014 18
  • Genital Warts (Condylomata Acuminata) - Pipeline by NanoViricides, Inc., H2 2014 19
  • Assessment by Monotherapy Products, H2 2014 20
  • Number of Products by Stage and Target, H2 2014 22
  • Number of Products by Stage and Mechanism of Action, H2 2014 24
  • Number of Products by Stage and Route of Administration, H2 2014 26
  • Number of Products by Stage and Molecule Type, H2 2014 28
  • Genital Warts (Condylomata Acuminata) Therapeutics - Recent Pipeline Updates, H2 2014 39
  • Genital Warts (Condylomata Acuminata) - Dormant Projects, H2 2014 41
  • Genital Warts (Condylomata Acuminata) - Discontinued Products, H2 2014 42

List of Figures

  • Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2014 7
  • Number of Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H2 2014 8
  • Number of Products under Development by Companies, H2 2014 9
  • Comparative Analysis by Early Stage Products, H2 2014 11
  • Assessment by Monotherapy Products, H2 2014 20
  • Number of Products by Top 10 Targets, H2 2014 21
  • Number of Products by Stage and Top 10 Targets, H2 2014 22
  • Number of Products by Top 10 Mechanism of Actions, H2 2014 23
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 24
  • Number of Products by Top 10 Routes of Administration, H2 2014 25
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014 26
  • Number of Products by Top 10 Molecule Types, H2 2014 27
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014 28
Back to Top